standardized_cancer,raw_cancer,biomarker,therapy
Invasive Breast Carcinoma,early breast cancer,"HER2-negative [present], ER positive [present]",Tamoxifen + Abemaciclib
Invasive Breast Carcinoma,advanced or metastatic breast cancer,"HER2-negative [present], ER positive [present]",Anastrozole + Abemaciclib
Prostate Adenocarcinoma,metastatic castration-resistant prostate cancer,BARD1 oncogenic variants [present],Prednisone + Niraparib + Abiraterone acetate
Non-Small Cell Lung Cancer,locally advanced or metastatic non-small cell lung cancer,KRAS p.G12C [present],Adagrasib
Invasive Breast Carcinoma,metastatic breast cancer,HER2-positive [present],Trastuzumab emtansine
Non-Small Cell Lung Cancer,metastatic non-small cell lung cancer,EGFR somatic variants [present],Afatinib
Non-Small Cell Lung Cancer,non-small cell lung cancer,v::ALK [present],Alectinib
APL with PML-RARA,low-risk acute promyelocytic leukemia (APL),PML::RARA [present],Arsenic trioxide
APL with PML-RARA,acute promyelocytic leukemia (APL),PML::RARA [present],Arsenic trioxide
Chronic Myelogenous Leukemia,philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML),BCR::ABL1 [present],Asciminib
Non-Small Cell Lung Cancer,metastatic non-squamous non-small cell lung cancer,"Wild type EGFR [present], Wild type ALK [present]",Carboplatin + Paclitaxel + Bevacizumab + Atezolizumab
Melanoma,unresectable or metastatic melanoma,BRAF p.V600E [present],Vemurafenib + Cobimetinib + Atezolizumab
Gastrointestinal Stromal Tumor,unresectable or metastatic GIST,PDGFRA p.D842V [present],Avapritinib
Acute Lymphoid Leukemia,b-cell precursor acute lymphoblastic leukemia (ALL),CD19 + [present],Blinatumomab
Acute Lymphoid Leukemia,b-cell precusor acute lymphoblastic leukemia (ALL),"BCR::ABL1 [not present], CD19 + [present]",Blinatumomab
Chronic Myelogenous Leukemia,philadelphia chromosome-positive chronic myelogenous leukemia (CML),BCR::ABL1 [present],Bosutinib
Anaplastic Large Cell Lymphoma,"systemic anaplastic large cell lymphoma (sALCL) or other CD30-expressing peripheral T-cell lymphomas (PTCL), including angioimmunoblastic T-cell lymphoma and PTCL not otherwise specified",CD30 + [present],Doxorubicin + Prednisone + Brentuximab vedotin + Cyclophosphamide
Anaplastic Large Cell Lymphoma,cutaneous analastplci large cell lymphoma (pcALCL) or CD30-expressing mycosis fungoides (MF),CD30 + [present],Brentuximab vedotin
Adenocarcinoma of the Gastroesophageal Junction,metastatic gastric or gastroesophageal junction adenocarcinoma,HER2-positive [present],Capecitabine
Invasive Breast Carcinoma,locally advanced or metastatic breast cancer,"HER2-negative [present], ER positive [present], PIK3CA somatic variants [present]",Fulvestrant + Capivasertib
Colorectal Adenocarcinoma,metastatic colorectal cancer,"EGFR positive [present], Wild type KRAS [present]",Fluorouracil + Irinotecan + Cetuximab
Anaplastic Large Cell Lymphoma,anaplastic large cell lymphoma (ALCL),v::ALK [present],Crizotinib
Inflammatory Myofibroblastic Tumor,"unresectable, recurrent, or refractory inflammatory myofibroblastic tumor (IMT)",v::ALK [present],Crizotinib
Melanoma,melanoma,BRAF p.V600E [present],Trametinib + Dabrafenib
Anaplastic Thyroid Cancer,locally advanced or metastatic anaplastic thyroid cancer (ATC),BRAF p.V600E [present],Trametinib + Dabrafenib
Any solid tumor,unresectable or metastatic solid tumors,BRAF p.V600E [present],Trametinib + Dabrafenib
"Low-Grade Glioma, NOS",low-grade glioma (LGG),BRAF p.V600E [present],Trametinib + Dabrafenib
Chronic Myelogenous Leukemia,philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML),BCR::ABL1 [present],Dasatinib
"Chronic Myeloid Leukemia, BCR-ABL1+",philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML),BCR::ABL1 [present],Dasatinib
Chronic Myelogenous Leukemia,"chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML",BCR::ABL1 [present],Dasatinib
"Chronic Myeloid Leukemia, BCR-ABL1+","chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML",BCR::ABL1 [present],Dasatinib
Acute Lymphoid Leukemia,philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL),BCR::ABL1 [present],Dasatinib
Chronic Myelogenous Leukemia,philadelphia chromosome-positive CML,BCR::ABL1 [present],Dasatinib
"Chronic Myeloid Leukemia, BCR-ABL1+",philadelphia chromosome-positive CML,BCR::ABL1 [present],Dasatinib
Acute Lymphoid Leukemia,philadelphia chromosome-positive ALL,BCR::ABL1 [present],Dasatinib
Endometrial Carcinoma,primary advanced or recurrent endometrial cancer,dMMR [present],Carboplatin + Dostarlimab + Paclitaxel
Endometrial Carcinoma,recurrent or advanced endometrial cancer,dMMR [present],Dostarlimab
Any solid tumor,recurrent or advanced solid tumors,dMMR [present],Dostarlimab
Acute Myeloid Leukemia,relapsed or refractory acute myeloid leukemia (AML),IDH2 p.R140Q [present],Enasidenib
Any solid tumor,solid tumors,v::NTRK1 [present],Entrectinib
Bladder Urothelial Carcinoma,locally advanced or metastatic urothelial carcinoma (mUC),FGFR3 p.R248C [present],Erdafitinib
Invasive Breast Carcinoma,breast cancer,"HER2-negative [present], ER positive [present]",Exemestane + Everolimus
Intrahepatic Cholangiocarcinoma,"unresectable, locally or metastatic intrahepatic cholangiocarcinoma",FGFR2::v [present],Futibatinib
Acute Lymphoid Leukemia,acute myeloid leukemia,CD33 + [present],Gemtuzumab ozogamicin
Acute Lymphoid Leukemia,relapsed or refractory acute myeloid leukemia,FLT3-ITD [present],Gilteritinib
Chronic Myelogenous Leukemia,philadelphia chromosome-positive chronic myeloid leukemia,BCR::ABL1 [present],Imatinib
"Chronic Myeloid Leukemia, BCR-ABL1+",philadelphia chromosome-positive chronic myeloid leukemia,BCR::ABL1 [present],Imatinib
Acute Lymphoid Leukemia,philadelphia chromosome-positive acute lymphoblastic leukemia,BCR::ABL1 [present],Imatinib
Myelodysplastic Syndromes,myelodyplastic/myeloproliferative diseases (MDS/MPD),PDGFRA rearrangements [present],Imatinib
Aggressive Systemic Mastocytosis,aggressive systemic mastocytosis (ASM),KIT p.D816V [not present],Imatinib
"Chronic Eosinophilic Leukemia, NOS",hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL),FIP1L1::PDGFRA [present],Imatinib
Gastrointestinal Stromal Tumor,unresectable and/or metastatic maligant gastrointestinal stromal tumors (GIST),CD117 + [present],Imatinib
Gastrointestinal Stromal Tumor,GIST,FIP1L1::PDGFRA [present],Imatinib
Cholangiocarcinoma,unresectable locally advanced or metastatic cholangiocarcinoma,FGFR2::v [present],Infigratinib
Acute Lymphoid Leukemia,B-cell precursor acute lymphoblastic leukemia (ALL),CD22 + [present],Inotuzumab ozogamicin
Non-Small Cell Lung Cancer,metastatic or recurrent non-small cell lung cancer,"Wild type EGFR [present], Wild type ALK [present]",Carboplatin + Nivolumab + Ipilimumab + Pemetrexed
Acute Myeloid Leukemia,acute myeloid leukemia,IDH1 p.R132C [present],Ivosidenib
Acute Myeloid Leukemia,relapsed or refractory AML,IDH1 p.R132C [present],Ivosidenib
Myelodysplastic Syndromes,relapsed or refractory myelodysplastic syndromes,IDH1 p.R132C [present],Ivosidenib
Cholangiocarcinoma,locally advanced or metastatic cholangiocarcinoma,IDH1 p.R132C [present],Ivosidenib
Myelodysplastic Syndromes,transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS),5q deletion [present],Lenalidomide
Invasive Breast Carcinoma,early-stage breast cancer,HER2-positive [present],Neratinib
Chronic Myelogenous Leukemia,philadelphia chromosome-positive chronic myeloid (Ph+ CML),BCR::ABL1 [present],Nilotinib
"Chronic Myeloid Leukemia, BCR-ABL1+",philadelphia chromosome-positive chronic myeloid (Ph+ CML),BCR::ABL1 [present],Nilotinib
Chronic Myelogenous Leukemia,chronic phase or accelerated phase Ph+ CML,BCR::ABL1 [present],Nilotinib
"Chronic Myeloid Leukemia, BCR-ABL1+",chronic phase or accelerated phase Ph+ CML,BCR::ABL1 [present],Nilotinib
Ovarian Epithelial Tumor,"recurrent epithelial ovarian, fallopian tubem or primary peritoneal cancer",BRCA1 pathogenic variants [present],Niraparib
High-Grade Serous Fallopian Tube Cancer,"recurrent epithelial ovarian, fallopian tubem or primary peritoneal cancer",BRCA1 pathogenic variants [present],Niraparib
Peritoneal Serous Carcinoma,"recurrent epithelial ovarian, fallopian tubem or primary peritoneal cancer",BRCA1 pathogenic variants [present],Niraparib
Ovarian Epithelial Tumor,"advanced epithelial ovarian, fallopian tube or primary peritoneal cancer",BRCA1 oncogenic variants [present],Olaparib
High-Grade Serous Fallopian Tube Cancer,"advanced epithelial ovarian, fallopian tube or primary peritoneal cancer",BRCA1 oncogenic variants [present],Olaparib
Peritoneal Serous Carcinoma,"advanced epithelial ovarian, fallopian tube or primary peritoneal cancer",BRCA1 oncogenic variants [present],Olaparib
Ovarian Epithelial Tumor,"relapsed epithelial ovarian, fallopian tube or primary peritoneal cancer",BRCA1 oncogenic variants [present],Olaparib
High-Grade Serous Fallopian Tube Cancer,"relapsed epithelial ovarian, fallopian tube or primary peritoneal cancer",BRCA1 oncogenic variants [present],Olaparib
Peritoneal Serous Carcinoma,"relapsed epithelial ovarian, fallopian tube or primary peritoneal cancer",BRCA1 oncogenic variants [present],Olaparib
Invasive Breast Carcinoma,high risk early breast cancer,"HER2-negative [present], BRCA1 pathogenic variants [present]",Olaparib
Pancreatic Adenocarcinoma,metastatic pancreatic adenocarcinoma,BRCA1 pathogenic variants [present],Olaparib
Head and Neck Squamous Cell Carcinoma,"metastatic or unresectable, recurrent HNSCC",PD-L1 (CPS) >= 1 [present],Pembrolizumab
Any solid tumor,unresectable or metastatic ... solid tumors,dMMR [present],Pembrolizumab
Colorectal Adenocarcinoma,unresectable or metastatic ... colorectal cancer,dMMR [present],Pembrolizumab
Adenocarcinoma of the Gastroesophageal Junction,locally advanced unresectable or metastatic ... gastric or gastroesophageal junction (GEJ) adenocracinoma,"HER2-positive [present], PD-L1 (CPS) >= 1 [present]",Trastuzumab + Fluorouracil + Cisplatin + Pembrolizumab
Adenocarcinoma of the Gastroesophageal Junction,locally advanced unresectable or metastatic ... gastric or gastroesophageal junction (GEJ) adenocarcinoma,HER2-negative [present],Fluorouracil + Cisplatin + Pembrolizumab
Adenocarcinoma of the Gastroesophageal Junction,locally advanced or metastatic esophageal or gastroesophageal junction carcinoma,PD-L1 (CPS) >= 10 [present],Pembrolizumab
Esophageal Adenocarcinoma,locally advanced or metastatic esophageal or gastroesophageal junction carcinoma,PD-L1 (CPS) >= 10 [present],Pembrolizumab
Cervical Adenocarcinoma,"persistent, recurrent, or metastatic cervical cancer",PD-L1 (CPS) >= 1 [present],Paclitaxel + Cisplatin + Pembrolizumab
Cervical Squamous Cell Carcinoma,"persistent, recurrent, or metastatic cervical cancer",PD-L1 (CPS) >= 1 [present],Paclitaxel + Cisplatin + Pembrolizumab
Cervical Adenocarcinoma,recurrent or metastatic cervical cancer,PD-L1 (CPS) >= 1 [present],Pembrolizumab
Cervical Squamous Cell Carcinoma,recurrent or metastatic cervical cancer,PD-L1 (CPS) >= 1 [present],Pembrolizumab
Endometrial Carcinoma,advanced endometrial carcinoma,MSI-L [present],Lenvatinib + Pembrolizumab
Invasive Breast Carcinoma,high-risk early-stage triple-negative breast cancer,"ER negative [present], PR negative [present], HER2-negative [present]",Carboplatin + Doxorubicin + Paclitaxel + Cyclophosphamide + Pembrolizumab
Invasive Breast Carcinoma,locally recurrent unresectable or metastatic triple-negative breast cancer,"ER negative [present], PR negative [present], HER2-negative [present], PD-L1 (CPS) >= 10 [present]",Paclitaxel + Pembrolizumab
Myeloid/Lymphoid Neoplasms,relapsed or refractory myeloid/lymphoid neoplasms (MLNs),FGFR1 rearrangements [present],Pemigatinib
Invasive Breast Carcinoma,"locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive)",HER2-positive [present],Trastuzumab + Doxorubicin + Paclitaxel + Pertuzumab + Cyclophosphamide
Invasive Breast Carcinoma,early stage breast cancer,HER2-positive [present],Trastuzumab + Fluorouracil + Paclitaxel + Pertuzumab + Epirubicin + Cyclophosphamide
Acute Lymphoid Leukemia,Ph+ ALL,BCR::ABL1 [present],Prednisone + Ponatinib + Vincristine + Methotrexate + Cytarabine
Chronic Myelogenous Leukemia,CML,ABL1 p.T315I [present],Ponatinib
Papillary Thyroid Cancer,advanced or metastatic... thyroid cancer,v::RET [present],Pralsetinib
Non-Hodgkin Lymphoma,B-cell Non-Hodgkin's Lymphoma (NHL),CD20 + [present],Rituximab
Non-Hodgkin Lymphoma,Non-Hodgkin's Lymphoma (NHL),CD20 + [present],Doxorubicin + Prednisone + Vincristine + Rituximab + Cyclophosphamide
Non-Hodgkin Lymphoma,diffuse large B-cell Non-Hodgkin's Lymhpoma (NHL),CD20 + [present],Doxorubicin + Prednisone + Vincristine + Rituximab + Cyclophosphamide
Diffuse Large B-Cell Lymphoma,"mature B-cell NHL and mature B-cell acute leukemia (B-AL) previously untreated, advanced stage, CD20-positive, diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), Burkitt-like lymphoma (BLL) or mature B-cell acute leukemia (B-AL)",CD20 + [present],Doxorubicin + Prednisone + Vincristine + Rituximab + Cyclophosphamide
Burkitt Lymphoma,"mature B-cell NHL and mature B-cell acute leukemia (B-AL) previously untreated, advanced stage, CD20-positive, diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), Burkitt-like lymphoma (BLL) or mature B-cell acute leukemia (B-AL)",CD20 + [present],Doxorubicin + Prednisone + Vincristine + Rituximab + Cyclophosphamide
Mature B-Cell Neoplasms,"mature B-cell NHL and mature B-cell acute leukemia (B-AL) previously untreated, advanced stage, CD20-positive, diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), Burkitt-like lymphoma (BLL) or mature B-cell acute leukemia (B-AL)",CD20 + [present],Doxorubicin + Prednisone + Vincristine + Rituximab + Cyclophosphamide
Chronic Lymphocytic Leukemia,Chronic Lymphocytic Leuekmia (CLL),CD20 + [present],Rituximab + Fludarabine + Cyclophosphamide
Ovarian Epithelial Tumor,"epithelial ovarian, fallopian tube, or primary peritoneal cancer",BRCA1 oncogenic variants [present],Rucaparib
High-Grade Serous Fallopian Tube Cancer,"epithelial ovarian, fallopian tube, or primary peritoneal cancer",BRCA1 oncogenic variants [present],Rucaparib
Peritoneal Serous Carcinoma,"epithelial ovarian, fallopian tube, or primary peritoneal cancer",BRCA1 oncogenic variants [present],Rucaparib
Invasive Breast Carcinoma,unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC),"ER negative [present], PR negative [present], HER2-negative [present]",Sacituzumab govitecan
Invasive Breast Carcinoma,locally advanced or metastatic ... breast cancer,"HER2-negative [present], ER positive [present]",Sacituzumab govitecan
Medullary Thyroid Cancer,advanced or metastatic medullary thyroid cancer,RET oncogenic variants [present],Selpercatinib
Anaplastic Thyroid Cancer,advanced or metastatic thyroid cancer,v::RET [present],Selpercatinib
Any solid tumor,locally advanced or metastatic solid tumors,v::RET [present],Selpercatinib
Anaplastic Thyroid Cancer,locally advanced or metastatic anaplastic thyroid cancer,BRAF p.V600E [present],Trametinib + Dabrafenib
Gastrointestinal Stromal Tumor,metastatic gastric or gastroesophageal junction adenocarcinoma,HER2-positive [present],Trastuzumab
Invasive Breast Carcinoma,unresectable or metastatic breast cancer,HER2-positive [present],Trastuzumab deruxtecan
Invasive Breast Carcinoma,unresectable or metastatic ... breast cancer,HER2-low [present],Trastuzumab deruxtecan
Non-Small Cell Lung Cancer,unresectable or metastatic non-small cell lung cancer,ERBB2 oncogenic variants [present],Trastuzumab deruxtecan
Adenocarcinoma of the Gastroesophageal Junction,locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma,HER2-positive [present],Trastuzumab deruxtecan
Invasive Breast Carcinoma,advanced unresectable or metastatic breast cancer,HER2-positive [present],Trastuzumab + Capecitabine + Tucatinib
Non-Langerhans Cell Histiocytosis/Erdheim-Chester Disease,Erdheim-Chester Disease,BRAF p.V600E [present],Vemurafenib
Follicular Lymphoma,follicular lymphoma,EZH2 p.Y646N [present],Tazemetostat
Renal Angiomyolipoma,renal angiomyolipoma,TSC1 oncogenic variants [present],Everolimus
Anaplastic Thyroid Cancer,subependymal giant cell astrocytoma,TSC1 oncogenic variants [present],Everolimus
Ovarian Epithelial Tumor,"epithelial ovarian, fallopian tube, or primary peritoneal",FOLR1 positive [present],Mirvetuximab soravtansine
High-Grade Serous Fallopian Tube Cancer,"epithelial ovarian, fallopian tube, or primary peritoneal",FOLR1 positive [present],Mirvetuximab soravtansine
Peritoneal Serous Carcinoma,"epithelial ovarian, fallopian tube, or primary peritoneal",FOLR1 positive [present],Mirvetuximab soravtansine
Colorectal Adenocarcinoma,colorectal cancer,KRAS p.G12C [present],Adagrasib + Cetuximab
Astrocytoma,astrocytoma or oligodendroglioma,IDH1 p.R132C [present],Vorasidenib
Oligodendroglioma,astrocytoma or oligodendroglioma,IDH1 p.R132C [present],Vorasidenib
Adenocarcinoma of the Gastroesophageal Junction,gastric or gastroesophageal junction adenocarcinoma,"HER2-negative [present], CLDN18.2 >= 75% [present]",Oxaliplatin + Fluorouracil + Zolbetuximab
Intraductal Papillary Neoplasm of the Bile Duct,biliary tract cancer (BTC),HER2-positive [present],Zanidatamab
Intracholecystic Papillary Neoplasm,biliary tract cancer (BTC),HER2-positive [present],Zanidatamab
Cholangiocarcinoma,biliary tract cancer (BTC),HER2-positive [present],Zanidatamab
Pancreatic Adenocarcinoma,pancreatic adenocarcinoma,v::NRG1 [present],Zenocutuzumab
"Chronic Myeloid Leukemia, BCR-ABL1+",philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML),BCR::ABL1 [present],Asciminib
Acute Lymphoid Leukemia,acute leukemia,t(KMT2A;v) [present],Revumenib
Acute Myeloid Leukemia,acute leukemia,t(KMT2A;v) [present],Revumenib
Burkitt Lymphoma,acute leukemia,t(KMT2A;v) [present],Revumenib
Acute Leukemias of Ambiguous Lineage,acute leukemia,t(KMT2A;v) [present],Revumenib
Lung Non-Squamous Non-Small Cell Carcinoma,non-squamous non-small cell lung cancer,c-Met >= 50% [present],Telisotuzumab Vedotin
Low-Grade Serous Ovarian Cancer,low-grade serous ovarian cancer (LGSOC),KRAS p.G12C [present],Avutometinib + Defactinib
Chronic Myelogenous Leukemia,Ph+ CML-CP and CML-AP,BCR::ABL1 [present],Nilotinib
"Chronic Myeloid Leukemia, BCR-ABL1+",Ph+ CML-CP and CML-AP,BCR::ABL1 [present],Nilotinib
Head and Neck Squamous Cell Carcinoma,head and neck squamous cell cancer,PD-L1 (CPS) >= 1 [present],Pembrolizumab
Invasive Breast Carcinoma,non-small cell lung cancer,EGFR Exon 20 (Insertion) [present],Datopotamab deruxtecan
Non-Small Cell Lung Cancer,breast cancer,"PR positive [present], HER2-negative [present]",Datopotamab deruxtecan
Non-Small Cell Lung Cancer,non-small cell lung cancer (NSCLC),EGFR Exon 20 (Insertion) [present],Sunvozertinib
